Some studies have used numerous biomarkers for prompt detection and predicting severity of AKI and thereby categorizing into appropriate risk groups at risk for progressive renal decline, requirement of RRT, or death.5–7 Biomarkers like interleukin-18 (IL-18), cystatin C (Cys C), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and liver-type fatty acid binding protein (L-FABP) are being used for prediction of AKI and probable recovery.6–8 Most of the tools to measure these biomarkers are expensive and not routinely available in all healthcare facilities. This evidence concerns the gene CST3 and acute kidney injury.